The INTERCEPT Studies
The INTERCEPT project aims to verify and clinically validate a panel of biomarkers and build a blood risk score through two studies spanning seven European countries that can identify individuals with a high risk of developing Crohn’s disease within five years after initial evaluation.
The PREDICT-CD Study
The study will recruit 10,000 healthy first-degree relatives of individuals with Crohn’s disease from seven European countries:
Interested in joining the PREDICT-CD Study?
Contact the study team in your country via the email address listed in the Contact Us section.
- Portugal
- Spain
- France
- Italy
- The Netherlands
- Poland
- Sweden
Through samples of serum - the fluid and solvent component of blood – provided by participants, the study will further validate the biomarkers and risk score.
From this group, 80 first-degree relatives with the highest risk of developing Crohn’s disease will be invited to take part in an innovative study aimed at preventing full-blown disease development through an established and highly effective medical treatment.
Eligibility Requirements for the Study
- You must be a first-degree relative of a patient with an established diagnosis of Crohn’s disease.
- Male or female between 16 and 35 years of age able to assent or consent.
- Able to understand information provided and give written informed assent or consent for the study.
Exclusion Criteria
- Prior diagnosis of Inflammatory Bowel Disease (IBD).
- Any legal or medical condition that limits the information and participation in the study.
- Inability to verify Crohn’s disease diagnosis in a first-degree relative.
- Unwilling or unable to provide informed written consent.
- Unwilling or unable to provide serum.
Frequently asked questions:
There are many questions associated with taking part in a clinical study. In order to answer these, kindly look through the following pamphlet on the PREDICT-CD Study.
